AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24225816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosupplementation with sodium bicarbonate and beta-alanine
Number of subjects: 36
Study 22807611 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan 50 mg
Number of subjects: 10
Study 22807611 — intervention group
Group type: COMPARATOR
Intervention: control condition (test meal alone)
Number of subjects: 10
Study 19680081 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation scenarios (roles: team leader, procedure chief, team member)
Number of subjects: 53
Study 19680081 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported learning values
Number of subjects: 53
Study 19680081 — intervention group
Group type: COMPARATOR
Intervention: Role in the scenario
Number of subjects: 53
Study 17472478 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipta alba (3 g/day in encapsulated form)
Number of subjects: 60
Study 17472478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 15590255 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA with lidocaine and clonidine (1 microg/kg)
Number of subjects: 84
Study 15590255 — intervention group
Group type: COMPARATOR
Intervention: IVRA with lidocaine only (normal saline)
Number of subjects: 84
Study 12217228 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturography
Number of subjects: 13
Study 12217228 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional EMG
Number of subjects: 13
Study 8122884 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 7
Study 8122884 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 7
Study 8122884 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 7
Study 2563465 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly tympanometry screening and subsequent treatment for OME
Number of subjects: 1439
Study 2563465 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 1439
Study 802644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 802644 — intervention group
Group type: EXPERIMENTAL
Intervention: RO3-4787
Number of subjects: 10
Study 802644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31829085 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-lb dumbbells
Number of subjects: 86
Study 31829085 — intervention group
Group type: COMPARATOR
Intervention: Handgrip exercise (squeezing rubber balls)
Number of subjects: 86
Study 31713296 — intervention group
Group type: EXPERIMENTAL
Intervention: Si-based film group (SiFG)
Number of subjects: 0
Study 31713296 — intervention group
Group type: EXPERIMENTAL
Intervention: Si-based film group after sandblasting (SiFSG)
Number of subjects: 0
Study 31713296 — intervention group
Group type: COMPARATOR
Intervention: Polished group (PG) zirconia
Number of subjects: 0
Study 31713296 — intervention group
Group type: COMPARATOR
Intervention: Sandblasted group (SG) zirconia
Number of subjects: 0
Study 28196255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (daily tablets containing 15 µg of major allergen Phleum p 5)
Number of subjects: 106
Study 28196255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched double-placebo injections)
Number of subjects: 106
Study 28196255 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (monthly injections containing 20 µg of Phleum p 5)
Number of subjects: 106
Study 25679998 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (High-Intensity Training)
Number of subjects: 33
Study 25679998 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT+VIB18 (High-Intensity Training with 18 Hz Whole-Body Vibration)
Number of subjects: 33
Study 25679998 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT+VIB30 (High-Intensity Training with 30 Hz Whole-Body Vibration)
Number of subjects: 33
Study 25679998 — intervention group
Group type: EXPERIMENTAL
Intervention: VIB30 (30 Hz Whole-Body Vibration)
Number of subjects: 33
Study 25679998 — intervention group
Group type: COMPARATOR
Intervention: Conventional HIT
Number of subjects: 33
Study 23593253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide vaccine
Number of subjects: 50
Study 23593253 — intervention group
Group type: COMPARATOR
Intervention: Ty21a vaccine
Number of subjects: 50
Study 23593253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 50
Study 21514731 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 21
Study 21514731 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 21
Study 19202155 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion VA bursts
Number of subjects: 128
Study 16926775 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir-SGC/ritonavir (1600 mg/100 mg)
Number of subjects: 171
Study 15344394 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once a day
Number of subjects: 40
Study 15344394 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice a day
Number of subjects: 40
Study 10937611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine for 14 weeks followed by placebo for 36 weeks
Number of subjects: 395
Study 10937611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine for 38 weeks followed by placebo for 12 weeks
Number of subjects: 395
Study 10937611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine for 50 weeks
Number of subjects: 395
Study 10937611 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 50 weeks
Number of subjects: 395
Study 9018854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacred music
Number of subjects: 0
Study 9018854 — intervention group
Group type: EXPERIMENTAL
Intervention: Secular music
Number of subjects: 0
Study 9018854 — intervention group
Group type: COMPARATOR
Intervention: All music combined
Number of subjects: 0
Study 8160538 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost (Cervagem)
Number of subjects: 40
Study 8160538 — intervention group
Group type: EXPERIMENTAL
Intervention: dinoproston (Cerviprost)
Number of subjects: 40
Study 3412741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 0
Study 3412741 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MTC)
Number of subjects: 0
Study 30240991 — intervention group
Group type: EXPERIMENTAL
Intervention: autoPSV
Number of subjects: 30
Study 30240991 — intervention group
Group type: COMPARATOR
Intervention: convPSV
Number of subjects: 30
Study 28639551 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet joint injections (FJIs) with local anaesthetic and corticosteroids (at up to six injection sites) plus best usual care (BUC)
Number of subjects: 26
Study 28639551 — intervention group
Group type: COMPARATOR
Intervention: Best usual care (BUC) alone
Number of subjects: 26
Study 24908148 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation (PR)
Number of subjects: 84
Study 24908148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Diazepam
Number of subjects: 84
Study 24908148 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment intervention)
Number of subjects: 84
Study 23731674 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogen therapy combined with exercise (AE)
Number of subjects: 80
Study 23731674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with exercise (CE)
Number of subjects: 80
Study 23731674 — intervention group
Group type: COMPARATOR
Intervention: Antiandrogen therapy without exercise (A)
Number of subjects: 80
Study 23731674 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without exercise (C)
Number of subjects: 80
Study 23731674 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise five times per week (supervised sessions for AE and CE)
Number of subjects: 80
Study 20890711 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mmHg external compression
Number of subjects: 24
Study 20890711 — intervention group
Group type: COMPARATOR
Intervention: Control forearm (no compression)
Number of subjects: 24
Study 20890711 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mmHg external compression
Number of subjects: 24
Study 20890711 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mmHg external compression
Number of subjects: 24
Study 18258423 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg formoterol fumarate inhalation solution twice daily plus tiotropium (FFIS/TIO)
Number of subjects: 0
Study 18258423 — intervention group
Group type: COMPARATOR
Intervention: Nebulized placebo twice daily plus tiotropium (PLA/TIO)
Number of subjects: 0
Study 17069557 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension (hang-back) recession technique
Number of subjects: 16
Study 17069557 — intervention group
Group type: COMPARATOR
Intervention: Conventional strabismus surgery
Number of subjects: 16
Study 12925055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 33
Study 12925055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10866909 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 12 mL of 0.75% ropivacaine
Number of subjects: 30
Study 10866909 — intervention group
Group type: COMPARATOR
Intervention: Multiple injections of 4 mL of 0.75% ropivacaine at each muscular twitch
Number of subjects: 30
Study 10866909 — intervention group
Group type: COMPARATOR
Intervention: Multiple injections
Number of subjects: 30
Study 10866909 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection
Number of subjects: 30
Study 10866909 — intervention group
Group type: EXPERIMENTAL
Intervention: Single group (n=15)
Number of subjects: 30
Study 10866909 — intervention group
Group type: COMPARATOR
Intervention: Multiple group (n=15)
Number of subjects: 30
Study 9357393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg every 24 hours (from day 11 to day 20) with losartan 100 mg every 24 hours
Number of subjects: 32
Study 9357393 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 300 mg every 12 hours
Number of subjects: 32
Study 7950612 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 100
Study 7950612 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers (conventional treatment)
Number of subjects: 100
Study 2886560 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg captopril BID
Number of subjects: 201
Study 2886560 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg captopril BID
Number of subjects: 201
Study 2886560 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the dose of captopril (Phase 3)
Number of subjects: 201
Study 2886560 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus diuretic (Phase 4)
Number of subjects: 201
Study 2886560 — intervention group
Group type: COMPARATOR
Intervention: Control group (beta blocker-diuretic treatment)
Number of subjects: 201
Study 2886560 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 201
Study 28985586 — intervention group
Group type: EXPERIMENTAL
Intervention: e-SBI
Number of subjects: 981
Study 28985586 — intervention group
Group type: COMPARATOR
Intervention: AO
Number of subjects: 981
Study 27295978 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with additional hip strengthening exercises
Number of subjects: 104
Study 27295978 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 24841015 — intervention group
Group type: EXPERIMENTAL
Intervention: High single scrotal incision
Number of subjects: 70
Study 24841015 — intervention group
Group type: COMPARATOR
Intervention: Classic inguinal approach
Number of subjects: 70
Study 23380881 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACE‐i)
Number of subjects: 70
Study 23380881 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 20826029 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (30 ml daily, 5 days/week) administered from day 1 of radiotherapy for Group 1 (prevention)
Number of subjects: 156
Study 20826029 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (30 ml daily, 5 days/week) administered from the onset of grade 2 mucositis for Group 2 (treatment)
Number of subjects: 156
Study 20826029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Actovegin)
Number of subjects: 156
Study 18097226 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI), cycles of 12 weeks on/off (408 participants)
Number of subjects: 813
Study 18097226 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART (CT; 405 participants)
Number of subjects: 813
Study 18097226 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART (CT)
Number of subjects: 813
Study 18097226 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI)
Number of subjects: 813
Study 17260226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape procedure
Number of subjects: 128
Study 17260226 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension
Number of subjects: 128
Study 14738685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 51
Study 14738685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus droperidol
Number of subjects: 51
Study 14738685 — intervention group
Group type: COMPARATOR
Intervention: Alizapride
Number of subjects: 51
Study 10793384 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvano-ceramic crowns (Auvo Galvano Crown)
Number of subjects: 410
Study 10793384 — intervention group
Group type: COMPARATOR
Intervention: Glass-ceramic individual crowns (Dicor)
Number of subjects: 410
Study 8832443 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked J-wire (Group M, n = 127)
Number of subjects: 303
Study 8832443 — intervention group
Group type: COMPARATOR
Intervention: Plain unmarked J-wire (Group UM, n = 176)
Number of subjects: 303
Study 1431925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thackray polyethylene plug (38 mm, disc-shaped)
Number of subjects: 77
Study 1431925 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone plug
Number of subjects: 77
Study 1431925 — intervention group
Group type: COMPARATOR
Intervention: Richard polyethylene plug (18.5 mm, bullet-shaped)
Number of subjects: 77
Study 2859703 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol once daily for 3 weeks
Number of subjects: 143
Study 2859703 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol in combination with 12.5 mg chlorthalidone for 3 weeks
Number of subjects: 143
Study 2859703 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol in combination with 25 mg chlorthalidone for 3 weeks
Number of subjects: 143
Study 2859703 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol or in combination with 12.5 mg or 25 mg CT for up to 12 months
Number of subjects: 143
Study 2859703 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 25 mg CT
Number of subjects: 143
Study 29552766 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar combined with cisplatin/pemetrexed chemotherapy
Number of subjects: 128
Study 29552766 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (pemetrexed and cisplatin)
Number of subjects: 128
Study 27314599 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI (effect‐site concentration=1.5 ng.mL‐1)
Number of subjects: 218
Study 27314599 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 218
Study 27314599 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Number of subjects: 218
Study 24850188 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + messaging intervention
Number of subjects: 469
Study 24850188 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 469
Study 23121149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 23121149 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg GEn
Number of subjects: 474
Study 23121149 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg GEn
Number of subjects: 474
Study 23121149 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg GEn
Number of subjects: 474
Study 19735259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 6
Study 19735259 — intervention group
Group type: COMPARATOR
Intervention: Baseline (untreated)
Number of subjects: 6
Study 18462268 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 0
Study 18462268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective β‐blockers
Number of subjects: 0
Study 18462268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective β‐blockers (with isosorbide‐5‐mononitrate)
Number of subjects: 0
Study 18462268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nonselective β‐blockers and EBL
Number of subjects: 0
Study 16170124 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-in prism glasses
Number of subjects: 72
Study 16170124 — intervention group
Group type: COMPARATOR
Intervention: Placebo reading glasses
Number of subjects: 72
Study 12855311 — intervention group
Group type: EXPERIMENTAL
Intervention: IA ketamine 10mg
Number of subjects: 45
Study 12855311 — intervention group
Group type: COMPARATOR
Intervention: IA saline 10ml
Number of subjects: 45
Study 12855311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-muscular ketamine 10mg
Number of subjects: 45
Study 10543581 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation for 2 weeks
Number of subjects: 0
Study 10543581 — intervention group
Group type: COMPARATOR
Intervention: Dimethicone for 2 weeks
Number of subjects: 0
Study 8720816 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 2 (manipulated frequency descriptors)
Number of subjects: 97
Study 8720816 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 3 (introduction with general information on side effects)
Number of subjects: 97
Study 8720816 — intervention group
Group type: COMPARATOR
Intervention: Version 1 (original side effects information)
Number of subjects: 97
Study 2049361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination sedation technique using nalbuphine and midazolam
Number of subjects: 2
Study 2049361 — intervention group
Group type: COMPARATOR
Intervention: Midazolam sedation alone
Number of subjects: 2
Study 6755207 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens with second-line drugs (cytosine arabinoside and asparaginase)
Number of subjects: 0
Study 6755207 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mercaptopurine
Number of subjects: 0
Study 6755207 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified induction period with less immunosuppression
Number of subjects: 0
Study 6755207 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous mercaptopurine (1-week gaps each month)
Number of subjects: 0
Study 6755207 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with ALL
Number of subjects: 0
Study 6755207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-typing by the FAB system
Number of subjects: 0
Study 31651842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone, administered twice daily for 48 hours
Number of subjects: 80
Study 31651842 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 48 hours
Number of subjects: 80
Study 27633946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tranexamic acid (IV and topical)
Number of subjects: 200
Study 27633946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV)
Number of subjects: 200
Study 27633946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular tranexamic acid
Number of subjects: 200
Study 27633946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 200
Study 26417720 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST/exercise
Number of subjects: 222
Study 24607889 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment (percutaneous plate via sinus tarsi approach)
Number of subjects: 108
Study 24607889 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (open reduction and internal fixation with conventional plate via L-shaped lateral approach)
Number of subjects: 108
Study 24607889 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment
Number of subjects: 108
Study 24607889 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 108
Study 24607889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 22210018 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 (3 or 10 mg/kg once weekly)
Number of subjects: 160
Study 22210018 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 386 (15 mg/kg once weekly)
Number of subjects: 160
Study 22210018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 19494090 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-delivered targeted exercise programme
Number of subjects: 0
Study 19494090 — intervention group
Group type: COMPARATOR
Intervention: Usual behaviour (control)
Number of subjects: 0
Study 17465000 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a and ribavirin for 48 weeks
Number of subjects: 234
Study 17465000 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a and ribavirin for 24 weeks
Number of subjects: 234
Study 14725849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) with GABAergic mechanisms
Number of subjects: 0
Study 14725849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) with glutamate reduction mechanisms
Number of subjects: 0
Study 14725849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with sustained effects on neuronal mechanisms
Number of subjects: 0
Study 14725849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with use-dependent impact on sodium or calcium channels
Number of subjects: 0
Study 14725849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with multiple mechanisms of action
Number of subjects: 0